Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.


Main menu starts here.
Skip the main menu to current location in your website.

Current location in your website.
Skip to main contents.

Pipeline

 

Place: Japan

Development No. Therapeutic Category Stage
T-3762 Injectable quinolone synthetic antibacterial agent Approval
T-614 Antirheumatic agent Preparing to file
T-705 Antiviral agent (Anti-influenza virus agent) Phase 3
T-5224 Antirheumatic agent (AP-1 inhibitor) Phase 2
T-3811 New type injectable quinolone synthetic antibacterial agent Phase 1
T-1106 Antiviral agent (Anti HCV agent) Non-clinical studies

(As of July 2010)

Place: Overseas

Development No. Therapeutic Category Stage
T-3811 New type quinolone synthetic antibacterial agent Preparing to file
T-817MA Treatment for Alzheimer's disease Phase 2
T-705 Antiviral agent (Anti-influenza virus agent) Phase 2
T-2307 Antifungal agent Phase 1
T-5224 Antirheumatic agent (AP-1 inhibitor) Phase 1

(As of July 2010)

Related Information

Main business fields that TOYAMA CHEMICAL concentrates.


Footer starts here.

Pages ends here.
Move to top of the page.